Expression level of lncRNA MIR210HG in high-grade serous ovarian cancer tissues and its correlation with clinicopathological features and prognosis

In: Discover Oncology · 2026 · doi:10.1007/s12672-026-05882-5 · W7210268970
article OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-09-21 ⓘ

This study found that lncRNA MIR210HG is upregulated in high-grade serous ovarian cancer and correlates with advanced stage, metastasis, and survival, while comparing expression levels to tissues from patients with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text ⓘ

This study investigated the expression of long non-coding RNA MIR210HG in high-grade serous ovarian cancer tissues and its association with clinicopathological features and patient prognosis. Researchers analyzed samples from 84 ovarian cancer patients and included a control group of 57 individuals who underwent surgery for uterine fibroids and adenomyosis, finding that MIR210HG was significantly upregulated in cancer tissues compared to normal controls. The results indicated that higher MIR210HG levels correlated with advanced clinical stage, lymph node metastasis, ascites, and poorer survival outcomes, particularly in patients with TP53 mutations. Relevance to endometriosis: listed as one indication for surgical resection in the control group, though the paper's main focus is high-grade serous ovarian cancer.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Objective To investigate long non-coding RNA (lncRNA) MIR210HG expression in high-grade serous ovarian cancer (HGSOC) and its correlation with clinicopathological features, clinical outcomes, and prognosis. Methods Tissue samples were collected from 84 patients with HGSOC undergoing surgical treatment at the Affiliated Hospital of Qingdao University from 2019 to 2021. Fifty-seven patients undergoing total hysterectomy and bilateral adnexectomy resection for uterine fibroids and adenomyosis during the same period were also included. MIR210HG expression was detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Univariate and multivariate logistic regression analyses were used to assess correlation with advanced FIGO stage and clinical outcomes. The Kaplan-Meier plotter was used to predict the correlation between MIR210HG expression and prognosis, considering pathological classification, clinical stage, and TP53 status. Results MIR210HG expression was significantly upregulated in HGSOC compared to normal ovarian and fallopian tube tissues. MIR210HG expression was moderately and weakly correlated with CA125 ( r = 0.515, P < 0.001) and HE4 levels ( r = 0.325, P = 0.001), respectively. Advanced clinical stage was associated with higher MIR210HG expression. Patients with lymph node metastasis and ascites also exhibited higher MIR210HG expression ( P < 0.05). MIR210HG was associated with FIGO stage, while CA125 ≤ 35 U/ml and FIGO stage II were independent protective factors for composite poor clinical outcomes. Patients with low MIR210HG expression had a significantly longer 5-year progression-free survival (PFS) compared to those with high expression. What’s more, MIR210HG expression was significantly correlated with both 5-year PFS and overall survival (OS) in TP53-mutant patients, as opposed to only OS in TP53 wild-type patients. Conclusion MIR210HG expression is significantly upregulated in HGSOC and is associated with clinical stage, lymph node metastasis, and ascites. MIR210HG expression exhibited survival associations based on TP53 status, suggesting biomarker potential for HGSOC.
Full text 4,508 characters · extracted from oa-html · 5 sections · click to expand

Abstract

Objective To investigate long non-coding RNA (lncRNA) MIR210HG expression in high-grade serous ovarian cancer (HGSOC) and its correlation with clinicopathological features, clinical outcomes, and prognosis.

Methods

Tissue samples were collected from 84 patients with HGSOC undergoing surgical treatment at the Affiliated Hospital of Qingdao University from 2019 to 2021. Fifty-seven patients undergoing total hysterectomy and bilateral adnexectomy resection for uterine fibroids and adenomyosis during the same period were also included. MIR210HG expression was detected via quantitative reverse transcription polymerase chain reaction (qRT-PCR). Univariate and multivariate logistic regression analyses were used to assess correlation with advanced FIGO stage and clinical outcomes. The Kaplan-Meier plotter was used to predict the correlation between MIR210HG expression and prognosis, considering pathological classification, clinical stage, and TP53 status.

Results

MIR210HG expression was significantly upregulated in HGSOC compared to normal ovarian and fallopian tube tissues. MIR210HG expression was moderately and weakly correlated with CA125 (r = 0.515, P < 0.001) and HE4 levels (r = 0.325, P = 0.001), respectively. Advanced clinical stage was associated with higher MIR210HG expression. Patients with lymph node metastasis and ascites also exhibited higher MIR210HG expression (P < 0.05). MIR210HG was associated with FIGO stage, while CA125 ≤ 35 U/ml and FIGO stage II were independent protective factors for composite poor clinical outcomes. Patients with low MIR210HG expression had a significantly longer 5-year progression-free survival (PFS) compared to those with high expression. What’s more, MIR210HG expression was significantly correlated with both 5-year PFS and overall survival (OS) in TP53-mutant patients, as opposed to only OS in TP53 wild-type patients.

Conclusion

MIR210HG expression is significantly upregulated in HGSOC and is associated with clinical stage, lymph node metastasis, and ascites. MIR210HG expression exhibited survival associations based on TP53 status, suggesting biomarker potential for HGSOC.

Acknowledgements

The authors thank Editage (www.editage.cn) for English language editing. Funding This work was supported by the Natural Science Fund Project of Shandong Province [ZR2019MH127] and the Key Research and Development Plan of Shandong Province [2019GSF108106]. Author information Authors and Affiliations Corresponding authors Ethics declarations Ethics approval and consent to participate The study was approved by the Ethical Committee of the Affiliated Hospital of Qingdao University (approval number: QYFY WZLL 27332). All methods were performed in accordance with the relevant guidelines and regulations of the Ethical Committee of the Affiliated Hospital of Qingdao University. All participants provided informed consent. Consent for publication All authors have consented to the publication of this article. Competing interests The authors declare no competing interests. Additional information Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary Information Below is the link to the electronic supplementary material. Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. About this article Cite this article Sun, N., Chen, A. Expression level of lncRNA MIR210HG in high-grade serous ovarian cancer tissues and its correlation with clinicopathological features and prognosis. Discov Onc (2026). https://doi.org/10.1007/s12672-026-05882-5 Received: Accepted: Published: DOI: https://doi.org/10.1007/s12672-026-05882-5

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-10-02T06:07:52.067649+00:00
License: CC0 · commercial use OK